<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[glaxo Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/glaxo.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to glaxo]]></description>
	<s:counts start="0" returned="20" found="49" />
	<language>en-us</language>
	<item>
		<title><![CDATA[U.S. Approves Glaxo H1N1 Vaccine]]></title>
		<link><![CDATA[http://www.bnet.com/2407-14055_23-363709.html]]></link>
		<description><![CDATA[NEW YORK (<a href="http://resources.bnet.com/index.php?source=ReutersUK">Reuters UK</a>) - GlaxoSmithKline Plc GSK has won U.S. marketing approval to sell an unadjuvanted H1N1 swine vaccine, allowing it to ship relatively modest amounts of scarce vaccine to the United States next month.The company said on Tuesday the Food and Drug Administration had approved a modified version...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Tue, 10 Nov 2009 22:45:39 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[Vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/h1n1+flu.html"><![CDATA[H1N1 Flu]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/noven+pharmaceuticals+inc..html"><![CDATA[Noven Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/oukbs.html"><![CDATA[Oukbs]]></category>
		<category domain="http://resources.bnet.com/topic/us.html"><![CDATA[US]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NOVN</category>
		<category domain="tickers">GSK,NOVN</category>
	</item>
	<item>
		<title><![CDATA[Glaxo Wins U.S. Approval For Swine Flu Vaccine]]></title>
		<link><![CDATA[http://www.bnet.com/2407-14055_23-363672.html]]></link>
		<description><![CDATA[NEW YORK (<a href="http://resources.bnet.com/index.php?source=ReutersUK">Reuters UK</a>) - GlaxoSmithKline Plc GSK has won U.S. marketing approval to sell an unadjuvanted H1N1 swine vaccine, allowing it to ship relatively modest amounts of scarce vaccine to the United States next month.The British company said on Tuesday the Food and Drug Administration had approved a modified...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Tue, 10 Nov 2009 18:31:02 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[Vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/h1n1+flu.html"><![CDATA[H1N1 Flu]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/noven+pharmaceuticals+inc..html"><![CDATA[Noven Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/oukbs.html"><![CDATA[Oukbs]]></category>
		<category domain="http://resources.bnet.com/topic/us.html"><![CDATA[US]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NOVN</category>
		<category domain="tickers">GSK,NOVN</category>
	</item>
	<item>
		<title><![CDATA[Amgen, Inc. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-325485.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator  Operator Instructions  The first question comes from the line of Geoff Meacham with J.P. Morgan. Geoff Meacham &#8211; J.P. Morgan   I wanted to ask a question on ONJ.  I know Roger mentioned that there weren&#8217;t many common features, but can you...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Mon, 27 Jul 2009 20:06:12 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/superiority.html"><![CDATA[Superiority]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/question.html"><![CDATA[Question]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/collaboration.html"><![CDATA[Collaboration]]></category>
		<category domain="http://resources.bnet.com/topic/groupware.html"><![CDATA[Groupware]]></category>
		<category domain="http://resources.bnet.com/topic/enterprise+software.html"><![CDATA[Enterprise Software]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[GSK Rapped in the UK for Tax Arrangements]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000905/gsk-rapped-in-the-uk-for-tax-arrangements/]]></link>
		<description><![CDATA[GlaxoSmithKline parceled out the legal locations of 40 drug brand names to various foreign countries such as Ireland and Puerto Rico in an effort to reduce the amount of tax it pays in the US and the UK, according to the Guardian. The result, the paper says is:  ...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Sat, 07 Feb 2009 17:59:18 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/u.k..html"><![CDATA[U.K.]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/taxes.html"><![CDATA[Taxes]]></category>
		<category domain="http://resources.bnet.com/topic/free+trade.html"><![CDATA[Free Trade]]></category>
		<category domain="http://resources.bnet.com/topic/personal+finance.html"><![CDATA[Personal Finance]]></category>
		<category domain="http://resources.bnet.com/topic/financial+planning.html"><![CDATA[Financial Planning]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Glaxo Reorganizing in U.S., Pfizer Urged to Keep Jobs in Connecticut, and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000361/pharma-roundup-glaxo-reorganizing-in-us-pfizer-urged-to-keep-jobs-in-connecticut-and-more/]]></link>
		<description><![CDATA[Glaxo reorganizes U.S. operations; Connecticut congressmen ask Pfizer to keep U.S. jobs; AstraZeneca executive Patterson to retire; DTC advertising not earning its keep? by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 04 Nov 2008 18:09:26 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/u.s..html"><![CDATA[U.S.]]></category>
		<category domain="http://resources.bnet.com/topic/job.html"><![CDATA[Job]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/connecticut.html"><![CDATA[Connecticut]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/recruitment+%2526+selection.html"><![CDATA[Recruitment & Selection]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce Management]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/u.s..html"><![CDATA[U.S.]]></category>
		<category domain="http://resources.bnet.com/topic/job.html"><![CDATA[Job]]></category>
		<category domain="http://resources.bnet.com/topic/advertisement.html"><![CDATA[Advertisement]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/connecticut.html"><![CDATA[Connecticut]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Pfizer and Glaxo Confirm Layoffs, Disclosure Mandated for Cephalon, and More]]></title>
		<link><![CDATA[http://www.bnet.com/5208-14054-0.html?forumID=1&threadID=3753&messageID=17681&start=0]]></link>
		<description><![CDATA[Pharma Roundup: Pfizer and Glaxo Confirm Layoffs, Disclosure Mandated for Cephalon, and MoreRE: Pharma Roundup: Pfizer and Glaxo Confirm Layoffs, Disclosure Mandated for Cephalon, and Morethe figures are very stuning and i was shocked after having look at the figures of Johnson & johnson but one thing which was disturbing...]]></description>
		<s:doctype><![CDATA[Discussion threads]]></s:doctype>
		<pubDate>Wed, 01 Oct 2008 21:55:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce management]]></category>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/roundup.html"><![CDATA[Roundup]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/layoff.html"><![CDATA[layoff]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">CEPH,PFE</category>
	</item>
	<item>
		<title><![CDATA[Glaxo Makes Like Ponce de Leon With Sirtris Buy]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/100039/glaxo-makes-like-ponce-de-leon-with-sirtris-buy/]]></link>
		<description><![CDATA[You can't fault GlaxoSmithKline for temerity. The U.K. drugmaker's unexpectedly large $720 million bid for Sirtris Pharmaceuticals represents a gutsy bet that the Massachusetts biotech really has a handle on a class of drugs that slow aging. Not that anyone at either company is eager to describe their work that...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 22 Apr 2008 18:24:35 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/sirtris.html"><![CDATA[Sirtris]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
	</item>
	<item>
		<title><![CDATA[Glaxo-Regulus Kicks Off an miRNA Land Grab]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/100032/glaxo-regulus-kicks-off-an-mirna-land-grab/]]></link>
		<description><![CDATA[GlaxoSmithKline's willingness to bet up to $600 million on a tiny biotech called Regulus Therapeutics kicks off the latest pharma land grab -- this one for treatments that rely on tiny molecules called microRNAs, or miRNAs for short.    New drug technologies -- or "modalities," as the industry...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 18 Apr 2008 06:34:25 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/mirna.html"><![CDATA[miRNA]]></category>
		<category domain="http://resources.bnet.com/topic/regulus+therapeutics.html"><![CDATA[Regulus Therapeutics]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
	</item>
	<item>
		<title><![CDATA[Glaxo Gets an FDA Warning... With Teeth]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/100010/glaxo-gets-an-fda-warning-with-teeth/]]></link>
		<description><![CDATA[Well before Vytorin became a cause cÃ©lÃ¨bre -- which is to say, about a year ago -- GlaxoSmithKline was the drugmaker getting slapped around by critics for downplaying or ignoring possible heart problems associated with its diabetes drug Avandia. That case, which led to new warnings on the drug's label...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Sat, 12 Apr 2008 12:56:47 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/avandia.html"><![CDATA[Avandia]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
	</item>
	<item>
		<title><![CDATA[Congress lambastes FDA over risks related to diabetes drug]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_qn4176/is_20070607/ai_n19295229]]></link>
		<description><![CDATA[WASHINGTON -- Safety concerns about a GlaxoSmithKline diabetes drug prompted some Democratic lawmakers on Wednesday to rebuke the Food and Drug Administration and call for increased regulation of the pharmaceutical industry.    The controversy surrounding Glaxo's Avandia intensified when a medical expert told Congress that executives threatened to...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 07 Jun 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avandia.html"><![CDATA[Avandia]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+congress.html"><![CDATA[U.S. Congress]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Glaxo, U.S. settle transfer pricing dispute.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb4692/is_200702/ai_n19246864]]></link>
		<description><![CDATA[Byline: Audrey Nutt    Feb 05, 2007 (Tax Notes International - ABIX via COMTEX) -- The US  Internal Revenue Service IRS has reported details of a settlement with  GlaxoSmithKline Glaxo. The $US3.4 billion settlement, announced on 11  September 2006, relates to a transfer pricing dispute...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 05 Feb 2007 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/internal+revenue+service.html"><![CDATA[Internal Revenue Service]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/settlement.html"><![CDATA[settlement]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Glaxo takes on Merck.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb6602/is_200701/ai_n26023592]]></link>
		<description><![CDATA[GlaxoSmithKline has taken the brave step of pitting its new  cervical cancer vaccine, Cervarix, head-to-head against rival  Merck's product, Gardasil. Over a period of 12 months, the Phase  III trial will compare the immune responses of female patients   GlaxoSmithKline has taken the brave step of...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 26 Jan 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Glaxo, insurer dispute coverage for Paxil suits; Complaints allege drugmaker tried to curb competition.(News)(GlaxoSmithKline PLC)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5252/is_200612/ai_n20180065]]></link>
		<description><![CDATA[Byline: DOUGLAS McLEOD    PHILADELPHIA-GlaxoSmithKline P.L.C. is suing one of its liability  insurers for denying coverage for a series of disputes in which the  pharmaceutical giant has been charged with trying to restrain generic  competitors of its a  Byline: DOUGLAS McLEOD   ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 11 Dec 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[drug company]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">GSK</category>
	</item>
	<item>
		<title><![CDATA[11: David Stout; President-pharmaceuticals, GlaxoSmithKline.(Special Report: Power Players)(Brief article)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb6398/is_200610/ai_n25579584]]></link>
		<description><![CDATA[POWER PLAY: David Stout has GSK in a good spot. Glaxo has a strong  franchise in its diabetes medications and asthma inhaler Advair. Its  pipeline is considered good. It has sought FDA approval for cervical  cancer vaccine Cervarix, as well as migraine   POWER PLAY: David...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 09 Oct 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">GSK</category>
	</item>
	<item>
		<title><![CDATA[IRS, Glaxo agree on big settlement]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_qn4188/is_20060912/ai_n16717593]]></link>
		<description><![CDATA[WASHINGTON -- Drug giant GlaxoSmithKline agreed to pay $3.4 billion in the largest tax settlement in IRS history, resolving a dispute from the 1980s over the multinational company's U.S. profits.   The disagreement concerned how much of the profits from certain drugs, particularly the ulcer and heartburn medication Zantac,...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 12 Sep 2006 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/internal+revenue+service.html"><![CDATA[Internal Revenue Service]]></category>
		<category domain="http://resources.bnet.com/topic/settlement.html"><![CDATA[settlement]]></category>
		<category domain="http://resources.bnet.com/topic/taxes.html"><![CDATA[Taxes]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Glaxo withdraws AIDS drug patent plan in Thailand, India]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_kmafp/is_200608/ai_n16678694]]></link>
		<description><![CDATA[BANGKOK AFP &#8212; British pharmaceutical firm GlaxoSmithKlein has dropped its controversial application to patent a key AIDS drug in Thailand and India, the company and international HIV campaigners have said.  Glaxo, which introduced the drug Combid to Thailand four years ago, told AFP that it had informed the Thai...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 17 Aug 2006 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agence+france-presse.html"><![CDATA[Agence France-Presse]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/thailand.html"><![CDATA[Thailand]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Trana Discovery Teams with Former Glaxo Executives to Fight Drug-Resistant Infectious Diseases; Company Will Commercialize North Carolina State University Drug Discovery Technology]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_April_27/ai_n26841314]]></link>
		<description><![CDATA[CARY, N.C. -- A veteran team of five former Glaxo executives has joined Trana Discovery, Inc. formerly known as Neos Discovery to commercialize technology that identifies drug compounds that interrupt the lifecycle of pathogens through a novel mechanism of action - the inhibition of transfer ribonucleic acid tRNA. The use...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 27 Apr 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/north+carolina+state+university.html"><![CDATA[North Carolina State University]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Rockville-based biotech collects  $5M, gains ground on anthrax]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_qn4183/is_20060111/ai_n15992730]]></link>
		<description><![CDATA[With millions of dollars coming in and its anthrax therapy nearing availability, Human Genome Sciences Inc. said its 2005 numbers will be better than expected and that its outlook for 2006 is good and improving. The Rockville-based biotechnology firm announced yesterday that it recently collected $5 million from a partner,...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 11 Jan 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[GLAXOSMITHKLINE (GSK).]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb6602/is_200512/ai_n26019014]]></link>
		<description><![CDATA[1,451p - Pharmaceuticals - After a decent performance in 2005,  GlaxoSmithKline's shares have weakened due to concerns about the  company's asthma drug, Advair. US regulators have demanded that  Glaxo place a 'black box' on the drug's packaging,  warnin  1,451p - Pharmaceuticals - After a decent...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 30 Dec 2005 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/asthma.html"><![CDATA[asthma]]></category>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/regulator.html"><![CDATA[regulator]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">GSK</category>
	</item>
	<item>
		<title><![CDATA[Andrx Sues GlaxoSmithKline plc for Infringement of Andrx's Patent for the Formulation of a Once Daily Dosage Form of 150mg Bupropion]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2005_Dec_20/ai_n15955167]]></link>
		<description><![CDATA[FORT LAUDERDALE, Fla. -- Andrx Corporation (Nasdaq:ADRX) ("Andrx" or "Company") announced today that it has filed a patent infringement lawsuit in the U.S. District Court for the Southern District of Florida against GlaxoSmithKline plc and SmithKline Beecham Corporation (collectively "Glaxo"). The Company believes Glaxo's currently marketed formulation of Wellbutrin XLR...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 20 Dec 2005 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/glaxo.html"><![CDATA[Glaxo]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">GSK</category>
	</item>
</channel>
</rss>
